Figure 5. Interaction between LOC646616 and miR-637. (A) qRT-PCR analysis of relative LOC646616 and miR-637 expression in PBMNCs from hypertensive subjects and normotensive controls. (B) qRT-PCR analysis of relative LOC646616 expression in 5 cell lines. GAPDH was used for normalization. (C) qRT-PCR analysis of miR-637 expression in HASMCs and HEK293T cells transfected with miR-637 mimics or mimic NC. (D) Transwell invasion assay results from HASMCs transfected with miR-637 or mimic NC. (E) Results of CCK-8 viability assays in HASMCs with and without enforced miR-637 overexpression. (F) RIP assay results showing co-precipitation of LOC646616 and miR-637 by an Ago2 antibody in HASMCs. Verification of RIP products by qRT-PCR is also shown. (G) Bioinformatics evidence of the interaction between miR-637 and LOC646616, schematic diagram of the mutant LOC646616 luciferase reporter sequence, and results of luciferase activity assays in HEK293T cells co-expressing miR-637 mimics or mimic NC and reporter plasmids containing wild type (wt) or mutant (mut) LOC646616 sequences. Data are presented as the mean ± SD. *P<0.05, **P<0.01.